Results 131 to 140 of about 61,133 (325)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real‐World Analysis in Japanese Patients

open access: yesCancer Science, EarlyView.
In this study, we investigated the predictive value of tumor mutational burden (TMB) for assessing the efficacy of pembrolizumab in a Japanese cohort. We analyzed real‐world data from 63,952 patients registered in the C‐CAT database who underwent comprehensive genomic profiling, and evaluated the therapeutic efficacy of pembrolizumab in 1899 of these ...
Tomoyo Yasuda   +7 more
wiley   +1 more source

Clinical significance of retrograde inferior parathyroid protection technique based on thymus preservation in thyroid surgery

open access: yesBMC Endocrine Disorders
Background The importance of parathyroid gland preservation in thyroid surgery has been well recognized; however, the rapid identification of the parathyroid gland, particularly the inferior parathyroid gland (IPG), remains challenging.
Shouyi Yan   +4 more
doaj   +1 more source

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

open access: yesHIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre   +2 more
wiley   +1 more source

MyD88 Deficiency Protects Mice From Experimental Autoimmune Encephalomyelitis by Influencing Both Dendritic Cells and T Cells

open access: yesImmunology, EarlyView.
This study investigates the role of MyD88 in dendritic cells (DCs) and T cells during experimental autoimmune encephalomyelitis (EAE). We found that MyD88 is highly expressed in DCs and CD4+ T cells in people with multiple sclerosis, and its deficiency impairs DC maturation, reduces pro‐inflammatory cytokine production, weakens DC–T cell interactions ...
Wen Si   +4 more
wiley   +1 more source

Autoimmunity and Periodontitis

open access: yesJournal of Periodontal Research, EarlyView.
In a microbe‐driven inflammatory environment, peptidyl‐arginine deiminase (PAD) enzymes from neutrophils and Porphyromonas gingivalis citrullinate both microbial and self‐antigens. B cell presentation of citrullinated or self‐mimicking epitopes activates T cells that assist B cells in antibody isotype switching, affinity maturation, epitope spreading ...
Massimo Costalonga   +2 more
wiley   +1 more source

PRE & POST-HATCHING DEVELOPMENT OF THE THYMUS GLAND IN CHICKEN [PDF]

open access: diamond, 2014
SOLIMAN SH.M.M.   +3 more
openalex   +1 more source

Prevention of Atopic Dermatitis in High‐Risk Infants: A Review of the Role of Lipid‐Based Barrier Repair Therapy

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Background/Objective Growing evidence highlights the role of physiological lipids, namely ceramides, cholesterol, and free fatty acids, in maintaining skin barrier function and preventing atopic dermatitis (AD). Current evidence on the efficacy, safety, and clinical relevance of stratum corneum (SC) lipid‐based therapies to prevent AD and ...
Chon‐Wai Jeremy Chan   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy